Our portfolio company, Cimeio Therapeutics, a biotechnology company that is reinventing cell therapy through its leadership in the emerging field of epitope shielding, and Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced a research collaboration to combine their respective technologies, including Prime Medicine’s Prime Editing platform and Cimeio’s Shielded Cell and Immunotherapy Pairs (SCIP) platform.
The goal of the research is to improve the safety and effectiveness of hematopoietic stem cell (HSC) transplants to treat genetic diseases, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS), as well as enable the in vivo selection of edited HSCs to potentially remove the need for transplantation entirely.
“Through this collaboration, we are bringing together industry-leading protein engineering and genome editing, with the potential to deliver safer, curative therapies for patients. Our aim is to eliminate the need for toxic chemotherapies and radiation and enable new therapeutic approaches post-transplant. Our goal is to reinvent HSC transplant as a more effective and practical option for many more patients facing debilitating and fatal diseases. We look forward to partnering with the extremely talented team at Prime Medicine to advance our novel CD117 program.” said Thomas Fuchs, Chief Executive Officer of Cimeio Therapeutics.
We are very excited for this collaboration and can’t wait to learn about the results!